258 related articles for article (PubMed ID: 28481188)
1. Eribulin long-term response and rechallenge: report of two clinical cases.
Barbieri E; Rubino D; Hakim R; Fini A; Lenzi M; Zamagni C
Future Oncol; 2017 Apr; 13(11s):35-43. PubMed ID: 28481188
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.
Morritti M; Iodice G; Melaccio A; D'Onofrio L; Bergnolo P; Boglione A; Comandone A; Molinaro P; Garigliano D
Future Oncol; 2017 Apr; 13(11s):25-33. PubMed ID: 28481183
[TBL] [Abstract][Full Text] [Related]
3. Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report.
Falco I; Stragliotto S
Future Oncol; 2017 Apr; 13(11s):51-54. PubMed ID: 28481187
[TBL] [Abstract][Full Text] [Related]
4. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
[TBL] [Abstract][Full Text] [Related]
5. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
Quaquarini E; Sottotetti F; D'Ambrosio D; Malovini A; Morganti S; Marinello A; Pavesi L; Frascaroli M
Future Oncol; 2017 Apr; 13(11s):11-23. PubMed ID: 28481185
[TBL] [Abstract][Full Text] [Related]
6. Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report.
Caputo R; Cianniello D; De Laurentiis M
Future Oncol; 2017 Apr; 13(11s):45-50. PubMed ID: 28481184
[TBL] [Abstract][Full Text] [Related]
7. Long response to eribulin in breast cancer: a case report.
Borgonovo K; Petrelli F; Cabiddu M; Ghilardi M; Coinu A; Seghezzi S; Barni S
Future Oncol; 2015; 11(15 Suppl):3-8. PubMed ID: 26235258
[TBL] [Abstract][Full Text] [Related]
8. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report.
Leo L; Caputo F; Sarno AD; Garofano T; Andreozzi F; Massaro MG; Montesarchio V
Future Oncol; 2015; 11(15 Suppl):27-30. PubMed ID: 26235262
[TBL] [Abstract][Full Text] [Related]
9. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.
Fabi A; Moscetti L; Ciccarese M; Caramanti M; Salesi N; La Verde N; Russillo M; Generali D; Scandurra G; Vari S; Pacetti U; Cognetti F; Giannarelli D
Future Oncol; 2015; 11(3):431-8. PubMed ID: 25675124
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
[TBL] [Abstract][Full Text] [Related]
11. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
O'Shaughnessy J; Kaklamani V; Kalinsky K
Future Oncol; 2019 May; 15(14):1641-1653. PubMed ID: 30892083
[TBL] [Abstract][Full Text] [Related]
13. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.
Lorusso V; Cinieri S; Latorre A; Porcu L; Del Mastro L; Puglisi F; Barni S
Future Oncol; 2017 May; 13(11):971-978. PubMed ID: 28326833
[TBL] [Abstract][Full Text] [Related]
15. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.
Poletti P; Ghilardi V; Livraghi L; Milesi L; Rota Caremoli E; Tondini C
Future Oncol; 2014 Feb; 10(2):233-9. PubMed ID: 24490609
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
[TBL] [Abstract][Full Text] [Related]
17. Eribulin mesylate for the treatment of late-stage breast cancer.
Gourmelon C; Frenel JS; Campone M
Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
[TBL] [Abstract][Full Text] [Related]
18. The safety of eribulin for the treatment of metastatic breast cancer.
Perez-Garcia JM; Cortes J
Expert Opin Drug Saf; 2019 May; 18(5):347-355. PubMed ID: 31107111
[No Abstract] [Full Text] [Related]
19. Advances in therapy: eribulin improves survival for metastatic breast cancer.
Morris PG
Anticancer Drugs; 2010 Nov; 21(10):885-9. PubMed ID: 20838209
[TBL] [Abstract][Full Text] [Related]
20. Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer.
Fujii T; Tokuda S; Nakazawa Y; Kurozumi S; Obayashi S; Yajima R; Shirabe K
In Vivo; 2020; 34(2):917-921. PubMed ID: 32111804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
